Ladiratuzumab Vedotin + Pembrolizumab for Advanced Cancers

Recruiting in Palo Alto (17 mi)

+72 other locations

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Seagen Inc.

No Placebo Group

Prior Safety Data

Breakthrough Therapy

Trial Summary

What is the purpose of this trial?This trial will study ladiratuzumab vedotin (LV) alone and with pembrolizumab to find out if it works to treat different types of solid tumors. It will also find out what side effects may occur. A side effect is anything the drug does besides treating cancer.

Eligibility Criteria

This trial is for adults with various advanced solid tumors who have already tried certain treatments without success. Participants must be in good physical condition (ECOG score of 0 or 1) and have measurable disease. Specific criteria apply to different cancer types, like only one prior chemotherapy for some or progression after platinum-based therapy. People with active brain tumors, recent radiotherapy, significant ongoing treatment side effects, or other cancers within the last three years can't join.

Participant Groups

The study tests ladiratuzumab vedotin alone and combined with pembrolizumab on patients with solid tumors to see if it's effective and safe. It targets those whose cancer has progressed despite previous treatments including chemotherapy and immunotherapy.

5Treatment groups

Experimental Treatment

Group I: Part C - Arm 3: Randomized LV combination therapyExperimental Treatment2 Interventions

Combination dosing schedule 2.

Group II: Part C - Arm 2: Randomized LV combination therapyExperimental Treatment2 Interventions

Combination dosing schedule 1.

Group III: Part C - Arm 1: Randomized LV monotherapyExperimental Treatment1 Intervention

Monotherapy dosing schedule 3.

Group IV: Part B: Non-randomized LV monotherapyExperimental Treatment1 Intervention

Monotherapy dosing schedule 2.

Group V: Part A: Non-randomized LV monotherapyExperimental Treatment1 Intervention

Monotherapy dosing schedule 1.